Spotlight
Clinical
CME/CE
Subscribe
- Benign Prostatic Hyperplasia
- Hormone Therapy
- Genomic Testing
- Next-Generation Imaging
- UTUC
- OAB and Incontinence
- Genitourinary Cancers
- Kidney Cancer
- Men's Health
- Pediatrics
- Female Urology
- Sexual Dysfunction
- Kidney Stones
- Urologic Surgery
- Bladder Cancer
- Benign Conditions
- Prostate Cancer
Study evaluates representation in urology drug trials
“The main finding of the study was that, like…other clinical trial studies in the past, we also found that there was an over representation of non-Hispanic White patients in these trials, and a dramatic under representation of people traditionally and historically underrepresented in clinical trials and in medicine,” says Kevin Koo, MD, MPH.
In this video, Kevin Koo, MD, MPH, discusses the background and notable findings from the study, “Disparities in race and ethnicity reporting in contemporary clinical trials leading to new drug approvals in urology,” which was presented at the North Central Section of the American Urological Association Annual Meeting in Chicago, Illinois. Koo is a urologist at Mayo Clinic in Rochester, Minnesota.
Related Videos
Related Content
